941685-26-3

Basic information

• Product Name: 4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE
• Synonyms: 4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE;7-((2-(triMethylsilyl)ethoxy)Methyl)-4-chloro-7H-pyrrolo[2,3-d]pyriMidine;7H-Pyrrolo[2,3-d]pyriMidine, 4-chloro-7-[[2-(triMethylsilyl)ethoxy]Methyl]-
• CAS NO: 941685-26-3
• Molecular Formula: C₁₂H₁₈ClN₃OSi
• Molecular Weight: 283.833
• EINECS: 1592732-453-0
• Mol File: 941685-26-3.mol
• Article Data: 37

Chemical Properties

• Boiling Point: 368.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.00±0.30(Predicted)
• CAS DataBase Reference: 4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(941685-26-3)
• EPA Substance Registry System: 4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(941685-26-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 941685-26-3(Hazardous Substances Data)

Usage

Uses

4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is used in the design and preparation of ruxolitinib-vorinostat conjugate derivatives which have dual inhibitory activity against Janus kinase (JAK) and histone deacetylase (HDAC).

Upstream product

• 3680-71-5 Allopurinol 
• 7400-06-8 6-amino-5-(2,2-diethoxyethyl)pyrimidin-4-ol 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1187595-88-5 4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 950661-94-6 4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
• 950661-91-3 5-bromo-4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 950661-92-4 4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid 
• 941685-27-4 4-(1H-pyrazol-4-yl)-7-((2-trimethylsilanylethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1334298-90-6 2-(1-{1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl}-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile 
• 1334302-63-4 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate 
• 1187594-09-7 Baricitinib 
• 1187594-13-3 2-[1-ethanesulfonyl-3-[4-(7-[(2-(trimethylsilyl)ethoxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl]acetonitrile 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF BARICITINIB

The present invention provides an improved process for the preparation of Baricitinib of formula (I),

Chemical Compounds

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.

Pyrrole/imidazo six-membered hetero-aromatic ring compound as well as preparation method and medical application thereof

The invention relates to a pyrrole/imidazo six-membered hetero-aromatic ring compound as well as a preparation method and medical application thereof. Particularly, the invention relates to a compoundas shown by general formula (I), a preparation method t